Marrosu Francesco, Bortolato Marco, Frau Roberto, Orrù Marco, Puligheddu Monica, Fà Mauro, Muroni Antonella, Tuveri Antonella, Mereu Giampaolo
Department of Neurological and Cardiovascular Sciences, University of Cagliari, Policlinico Universitario, S.S. 554 Km 4.500, 09042 Monserrato (CA), Italy.
Epilepsy Res. 2007 Jul;75(2-3):224-7. doi: 10.1016/j.eplepsyres.2007.05.008. Epub 2007 Jul 10.
Recent evidence highlights levetiracetam (LEV) as an advantageous treatment of absence epilepsy (AE). Thus, we investigated the effects of this drug in DBA/2J mice, a murine model of AE. Similarly to ethosuximide (200 mg/kg, intraperitoneal, i.p.) and sodium valproate (250 mg/kg, i.p.), two classic antiabsence agents, LEV (50-200 mg/kg, i.p.) reduced the occurrence of spike-and-wave discharges, AE's typical electroencephalographic patterns. Our results confirm LEV's efficacy in AE treatment.
近期证据表明,左乙拉西坦(LEV)是失神癫痫(AE)的一种有效治疗药物。因此,我们研究了该药物对DBA/2J小鼠(一种AE小鼠模型)的影响。与两种经典抗失神药物乙琥胺(200毫克/千克,腹腔注射,i.p.)和丙戊酸钠(250毫克/千克,i.p.)类似,LEV(50 - 200毫克/千克,i.p.)减少了棘波和慢波放电的发生,这是AE典型的脑电图模式。我们的结果证实了LEV在AE治疗中的疗效。